Metformin Inhibits Cell Motility and Proliferation of Triple-Negative Breast Cancer Cells by Blocking HMGB1/RAGE Signaling
Cells · 2025
DOI: 10.3390/cells14080590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Shazie Yusein-Myashkova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad G. Bonchev Str., Bl. 21, 1113 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Metformin, HMGB1 Protein, Triple Negative Breast Neoplasms, Cell Movement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bulgarian National Science Fund, Bulgarian National Scientific Fund.
Abstract (Originalsprache)
High-mobility group box 1 (HMGB1) is a nuclear chromatin protein overexpressed in various cancers and linked to tumor progression. Outside the cell, HMGB1 binds to receptors such as the receptor for advanced glycation end products (RAGE), promoting metastasis. Targeting this signaling pathway may provide a new therapeutic strategy for aggressive cancers. Metformin, a well-established antidiabetic drug, directly interacts with HMGB1, inhibiting its pro-inflammatory functions. This study investigates metformin’s effects on the HMGB1/RAGE signaling pathway in triple-negative breast cancer (TNBC) cells. Using wound-healing and colony formation assays, we demonstrate that metformin reduces HMGB1-induced cell migration and proliferation. Immunoblotting and immunofluorescence analyses reveal that metformin decreases RAGE stabilization on the cell membrane, disrupts NF-κB signaling, and reverses the epithelial-to-mesenchymal transition (EMT) by increasing E-cadherin, reducing vimentin, and stabilizing β-catenin at the cell membrane. Furthermore, metformin lowers HMGB1 and RAGE protein levels, disrupting the positive feedback loop that promotes cancer aggressiveness. These findings highlight metformin’s potential as a therapeutic agent in TNBC by inhibiting HMGB1/RAGE-driven metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad G. Bonchev Str., Bl. 21, 1113 Sofia, Bulgaria.
ORCID-Profile: Shazie Yusein-Myashkova, Anastas Gospodinov, Iva Ugrinova
Förderung
- Bulgarian National Science Fund
- Bulgarian National Scientific Fund
Zitieren
APA
Yusein-Myashkova, S., Vladimirova, D., Gospodinov, A., Ugrinova, I., & Todorova, J. (2025). Metformin Inhibits Cell Motility and Proliferation of Triple-Negative Breast Cancer Cells by Blocking HMGB1/RAGE Signaling. Cells. https://doi.org/10.3390/cells14080590
Vancouver
Yusein-Myashkova S, Vladimirova D, Gospodinov A, Ugrinova I, Todorova J. Metformin Inhibits Cell Motility and Proliferation of Triple-Negative Breast Cancer Cells by Blocking HMGB1/RAGE Signaling. Cells. 2025. doi:10.3390/cells14080590
BibTeX
@article{YuseinMyashkova2025,
author = {Yusein-Myashkova, Shazie and Vladimirova, Desislava and Gospodinov, Anastas and Ugrinova, Iva and Todorova, Jordana},
title = {Metformin Inhibits Cell Motility and Proliferation of Triple-Negative Breast Cancer Cells by Blocking HMGB1/RAGE Signaling},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14080590}
}
EUVIMED